COMPANY
Peptilogics
Peptilogics is a surgical therapeutics company advancing an anti-biofilm drug designed to cure and prevent all medical device-related infections. From company website Source · Oct 12, 2026
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Senior Clinical Trial Manager | Pittsburgh, Pennsylvania, United States, Remote | Aug 18, 2026 | Oct 5, 2026 |
| Director, Investor Relations & Communications | Pittsburgh, Pennsylvania, United States, Remote | Aug 6, 2026 | Oct 5, 2026 |
| Chief Financial Officer (CFO) | Pittsburgh, Pennsylvania, United States, Remote | Aug 6, 2026 | Oct 5, 2026 |
Raises and deals from press releases
- Raise Undisclosed round · $78M · announced Oct 16, 2025 Company release ↗
Source quote
- Oct 16, 2025 · Company release ↗
“Peptilogics Raises $78 Million to Advance Zaloganan Into Pivotal Trial”
- Oct 16, 2025 · Company release ↗
Timeline
- Board tracked Radar started tracking this company’s job board (3 open jobs at last check). source ↗
- Trial start Phase 2/Phase 3: Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infect source ↗
- Raise Undisclosed round · $78M source ↗
- Trial start Phase 1: Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA) source ↗
Upcoming milestones
- 2028-09 (ESTIMATED) · Phase 2/Phase 3 · Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Followi · NCT07214311
Open jobs 3
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Senior Clinical Trial Manager | Pittsburgh, Pennsylvania, United States, Remote | Aug 18, 2026 | Oct 5, 2026 | Senior |
| Director, Investor Relations & Communications | Pittsburgh, Pennsylvania, United States, Remote | Aug 6, 2026 | Oct 5, 2026 | Senior |
| Chief Financial Officer (CFO) | Pittsburgh, Pennsylvania, United States, Remote | Aug 6, 2026 | Oct 5, 2026 | Executive |
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07214311 | Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty | Phase 2/Phase 3 | Recruiting | Feb 3, 2026 | 2028-09 (estimated) |
| NCT05137314 | Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA) | Phase 1 | Completed | Mar 31, 2022 | Mar 19, 2024 (actual) |
Connect
See your connections at Peptilogics on LinkedIn (search by name, results not checked)